18
Participants
Start Date
August 19, 2018
Primary Completion Date
August 19, 2020
Study Completion Date
September 20, 2020
Low dose ET019002- T Cells
ET019002- T Cells are autologous T cells transduced expressing a novel anti-CD19 (ET019002) chimeric antigen receptor,and are administered by intravenous infusion with the dose of 0.75×10\*6/kg.
Middle dose ET019002- T Cells
ET019002- T Cells are autologous T cells transduced expressing a novel anti-CD19 (ET019002) chimeric antigen receptor,and are administered by intravenous infusion with the dose of 1.5×10\*6/kg.
High dose ET019002- T Cells
ET019002- T Cells are autologous T cells transduced expressing a novel anti-CD19 (ET019002) chimeric antigen receptor,and are administered by intravenous infusion with the dose of 3.0×10\*6/kg.
Collaborators (1)
Eureka Therapeutics Inc.
INDUSTRY
First Affiliated Hospital Xi'an Jiaotong University
OTHER